TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01275131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Study: NCT03265938

Intervention type: DEVICE
Intervention: Indirect Laryngoscopy
Description: The attending anesthesiologist will perform video laryngoscopy with the C-MAC D video laryngoscope and with the GlideScope AVL video laryngoscope and grade the view of the larynx obtained with each laryngoscope.
Study: NCT04112121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meeting with a Chaplain coupled with Biblical Readings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meeting with a Chaplain coupled with Biblical Readings
Study: NCT03378505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App
Description: Purposeful Living Mobile App JOOL to be used daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection
Description: Bi-weekly online reflection question
Study: NCT02292654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olipudase alfa
Description: Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
Study: NCT01924520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral
Study: NCT03871842

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Considering that the daily outpatient use of tDCS equipment is not feasible for most patients, the Pain and Neuromodulation group of the Hospital de Clínicas de Porto Alegre developed a portable tDCS device for home use that has a safe protocol, in addition of being easy to use so that the patient can use it at home without help. The safety protocol embedded in the device does not, for example, allow the appliance to be used for more than 20 minutes per day. The device can also provide the assisting staff with data such as the time the patient used the equipment, providing an accurate picture of the patient's adherence to this type of equipment. This tDCS equipment for home use has already been validated in a pilot study and will be used in this work.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The sham intervention will be applied exactly equal to active intervention, but the electric stimulus will last just for 30 seconds.
Study: NCT00978653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: 150 mg once a day
Study: NCT03945825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AF03
Description: A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AF03
Description: A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Delta Inulin-CpG55.2
Description: A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Delta Inulin-CpG55.2
Description: A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: 2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: 2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: 2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Seasonal Influenza Vaccine
Description: 2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Seasonal Influenza Vaccine
Description: 2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Seasonal Influenza Vaccine
Description: 2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
Study: NCT00690118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 45 mg/day, 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily, 18 months
Study: NCT00573495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT/Survivin Multi-Peptide Vaccine
Description: 100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
Study: NCT01090622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT00550875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass pollen allergenic extract (L. perenne-C. dactylon )
Description: Sublingual. 2 drops/daily 1000 DPP/ml 2 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass pollen allergenic extract (L. perenne-C. dactylon )
Description: Sublingual. 2 drops/daily 10000 DPP/ml 2 years

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sublingual. 2 drops/daily 2 years
Study: NCT02949466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
Study: NCT02518126

Intervention type: OTHER
Intervention: blood sample and tissue sample
Description: After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos

Intervention type: OTHER
Intervention: blood sample and tissue sample
Description: After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
Study: NCT03585413

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient-probiotic-combination
Description: Specific combined micronutrient-probiotic-supplement with different vitamins, minerals, phytochemicals and bioactive substances, and a mixture of 10 different probiotic bacteria.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Micronutrient-placebo-combination
Description: micronutrient (capsule)-placebo (powder)-supplement
Study: NCT03939091

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasonography
Description: Renal Ultrasonography
Study: NCT04049786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digestive biopsy
Description: All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Digestive biopsy are being performed in obese and post-RYGB patients for transcriptomic analysis
Study: NCT02747199

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYNERGY stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BVS ABSORB scaffold
Study: NCT04161495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efanesoctocog alfa (BIVV001)
Description: Pharmaceutical form: solution for injection Route of administration: IV injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efanesoctocog alfa (BIVV001)
Description: Pharmaceutical form: solution for injection Route of administration: IV injection
Study: NCT02319577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vinorelbine
Description: Anti-neoplastic drug (PO chemotherapeutical agent, vinka alkaloid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: EGFR tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: EGFR tyrosine kinase inhibitor
Study: NCT04433546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemziviptadil (PB1046)
Description: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemziviptadil (PB1046)
Description: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low Dose (10 mg) Control
Description: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)
Study: NCT03182452

Intervention type: OTHER
Intervention: Alarm Advisor
Description: Providing advice on alarm limits as part of routine medical care
Study: NCT04219397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication take back
Description: Patients will be provided with formal education about medication take back programs for left-over prescription medications. They will be provided with directions to the closest medication take back facility to their home, and directions to the closet medication take back facility near their post-operative clinic site, and instructed to dispose of any left-over oxycodone medication (at completion of analgesic therapy) through participating in medication take back.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication home disposal
Description: Patients and their families will be provided with formal education about how to use the medication home disposal kit: Dispose Rx, provided with a Dispose Rx home disposal kit, and instructed to dispose of any left-over oxycodone prescription medications with this kit following completion of analgesic therapy.
Study: NCT00125502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV gB vaccine
Description: CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59 adjuvant
Description: Oil-in-water emulsion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution
Study: NCT04188691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）
Description: Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）
Description: Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）
Description: Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum adjuvant
Description: Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
Study: NCT01757808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo at a dose of 500mg for one month followed by a dose of 1000mg.
Study: NCT03854045

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychiatry
Description: Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Description: Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist
Study: NCT00515632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balaglitazone
Description: One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balaglitazone
Description: One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balaglitazone
Description: One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balaglitazone
Description: One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
Study: NCT04578782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
Study: NCT03562247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care of IPF
Description: standard of care given to patients with IPF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care of IPF
Description: standard of care given to patients with IPF

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care of IPF
Description: standard of care given to patients with IPF
Study: NCT04049786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digestive biopsy
Description: All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Digestive biopsy are being performed in obese and post-RYGB patients for transcriptomic analysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digestive biopsy
Description: All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Digestive biopsy are being performed in obese and post-RYGB patients for transcriptomic analysis
Study: NCT03562247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telenursing
Description: scheduled phone calls with the patient and care giver
Study: NCT03562247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telenursing
Description: scheduled phone calls with the patient and care giver

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telenursing and Remote Monitoring
Description: scheduled phone calls and home monitoring of physiologic parameters
Study: NCT03302351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 30 patients will receive intravenous dexmedetomidine 1 mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 31 patients will receive intravenous ketamine 0.4 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmetedomidine+Ketamine
Description: 33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg + low dose ketamine 0.25mg/kg.
Study: NCT02798965

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: serodiagnosis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serodiagnosis
Study: NCT04580329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation (NMES) in addition to routine hospital care
Description: Patients in the NMES group will receive NMES sessions as the electrodes will be placed around the bilateral femoral quadriceps muscles and at the site of renal arteries.~NMES(\>100 Hz, 50-80 μ sec) will be performed for 55 min including 5 minutes for warm up and 5 minutes for recovery .~The intensity of electrical stimulation will be adjusted to suit the comfort level of each individual patient without producing discomfort or pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine hospital care without NMES
Description: routine hospital care include all the routine intervention done for post partum women with AKI including fluid resuscitation, diuretics, hemodialysis
Study: NCT03006731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Supervised HIIT sessions will be conducted on a treadmill at Toronto Rehab's Cardiac Rehabilitation and Secondary Prevention Program. During each of the three supervised HIIT sessions each week, subjects will be prescribed 2 protocols with a combination of short to moderate duration exercise of near maximal intensity alternating longer periods of active recovery. The total duration for each HIT session will be approximately 20 minutes with an additional 5 minutes warm-up and cool down period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Continuous Exercise
Description: MICE sessions represent the standard of care exercise prescription at TRI. Participants will be instructed to complete 20-60 minutes of continuous aerobic exercise at or around the ventilatory anaerobic threshold achieved on the cardiopulmonary exercise test.
Study: NCT04049786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 25mg
Description: Single-dose of carvedilol 25 mg are being administrated orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 25mg
Description: Single-dose of carvedilol 25 mg are being administrated orally.
Study: NCT03815786

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: 2-months oral administration of the symbiotic supplement (2 bags/day) + 1 month washout

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Symbiotic
Description: 2-months oral administration of the symbiotic supplement (2 bags/day) + 1 month washout

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2-months oral administration of the placebo (2 bags/day) + 1 month washout

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: 2-months oral administration of the placebo (2 bags/day) + 1 month washout
Study: NCT00304525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAF265
Description: A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAF265
Description: A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAF265
Description: A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAF265
Description: A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAF265
Description: A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
Study: NCT02112838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib 150 mg
Description: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib 100 mg
Description: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily by mouth, over the course of 24 weeks
Study: NCT05314920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive-behavioral therapy (TD-CBT)
Description: Transdiagnostic cognitive-behavioral therapy (TD-CBT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bernstein and Borkovec progressive muscle relaxation (PMR)
Description: Bernstein and Borkovec progressive muscle relaxation (PMR)